ClinicalTrials.gg
CompletedNCT02823145Updated Jul 14, 2025Results posted

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

A Phase 3 interventional study of ZX008 (Fenfluramine Hydrochloride) in Dravet Syndrome, sponsored by Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.. Completed at 67 sites in 12 countries. Open to participants aged 2 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
375
Allocation
Not applicable
Ages
2 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing fenfluramine in Epilepsies, Myoclonic — 2 open to participants now, 2 under way, none of them phase 3. Fenfluramine · Epilepsies, Myoclonic.

Enrollment
2nd of 11
375 · median 25
Started
2016
with 1 other
Phase 3
7 of 11
none open now
Registered
2nd of 11
by date
Lead sponsor
5 of 11
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

Among the 11 studies testing fenfluramine in Epilepsies, Myoclonic, this one is the 2nd largest by enrollment, is one of 2 that started in 2016, is one of 7 in phase 3, and was the 2nd registered.

Epilepsies, Myoclonic

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

Browse Epilepsies, Myoclonic studies →

Open to participants now

2 of the 11 studies testing fenfluramine in Epilepsies, Myoclonic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fenfluramine

Fenfluramine: first FDA approval 2020 (FINTEPLA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing fenfluramine in Epilepsies, Myoclonic, or all of them as a file.
02

Study summary

This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome.

Read the detailed description

This is an international, multicenter, open-label, long-term safety study of ZX008 in pediatric and young adult subjects with Dravet syndrome who participated in one of the core studies (ZX008-1501 and ZX008-1502) and are candidates for continuous treatment for an extended period of time. This trial will consist of a 36-month Open-Label Extension (OLE) Treatment Period and a 2-week Post-Dosing Period.

03

Conditions studied

  • Dravet Syndrome

Keywords

  • seizure
  • tonic clonic
  • epilepsy
  • myoclonic
  • encephalopathy
04

Who can participate

Ages eligible
2 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or non-pregnant, non-lactating female, age 2 to 18 years, inclusive as of the day of the core study Screening Visit.
  • Satisfactory completion of the core study in the opinion of the investigator and the sponsor.
  • Subjects who are >18 to ≤35 years of age at the time of screening and did not participate in one of the core studies may be eligible for participation.
  • A documented medical history to support a clinical diagnosis of Dravet syndrome, where convulsive seizures are not completely controlled by current antiepileptic drugs.
  • Parent/caregiver is willing and able to be compliant with diary completion, visit schedule and study drug accountability.
  • Subject's parent/caregiver has been compliant with diary completion during the core study, in the opinion of the investigator (eg, at least 90% compliant).

Key Exclusion Criteria:

  • Current or past history of cardiovascular or cerebrovascular disease, myocardial infarction or stroke.
  • Current cardiac valvulopathy or pulmonary hypertension that is and warrants discontinuation of study medication.
  • Current or past history of glaucoma.
  • Moderate or severe hepatic impairment.
  • Receiving concomitant therapy with: centrally-acting anorectic agents; monoamineoxidase inhibitors; any centrally-acting compound with clinically appreciable amount of serotonin agonist or antagonist properties, including serotonin reuptake inhibition; atomoxetine, or other centrally-acting noradrenergic agonist; cyproheptadine, and/or cytochrome P450 (CYP) 2D6/3A4/2B6 inhibitors/substrates.
  • Currently taking carbamazepine, oxcarbamazepine, eslicarbazepine, phenobarbital, or phenytoin, or has taken any of these within the past 30 days, as maintenance therapy.
  • A clinically significant condition, or has had clinically relevant symptoms or a clinically significant illness at Visit 1, other than epilepsy, that would negatively impact study participation, collection of study data, or pose a risk to the subject.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
375 participants (actual)

Study arms

  • Experimental
    ZX008

    ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).

    Drug: ZX008 (Fenfluramine Hydrochloride)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Open-label Extension (OLE) Treatment Period

    Treatment-emergent adverse events (TEAE) were defined as any AEs that based on start date information occurs after the first intake of study treatment.

    Time frame: From Day 1 to End of OLE Treatment Period - End of Study (EOS) Visit (Month 42)

  2. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the OLE Treatment Period

    A TEAE was defined as any AE that based on start date information occurs after the first intake of study treatment. Percentage of participants with TEAEs leading to withdrawal from IMP during OLE Treatment Period were reported.

    Time frame: From Day 1 to End of OLE Treatment Period - EOS Visit (Month 42)

  3. Percentage of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the OLE Treatment Period

    Serious Adverse event (SAE) was defined as any untoward medical occurrence that at any dose: • results in death, • is life-threatening threatening, • results in initial inpatient hospitalization or prolongation of hospitalization, •results in persistent or significant disability or incapacity, • results in a congenital anomaly/birth defect, • results in any medically significant event that did not meet any of the other 5 SAE criteria, but which was judged by a physician to potentially jeopardize the participant or require medical or surgical intervention to prevent one of the above outcomes listed as an SAE criterion.

    Time frame: From Day 1 to End of OLE Treatment Period - EOS Visit (Month 42)

Secondary outcomes

  1. Change From Baseline (Core) in Convulsive Seizure Frequency Per 28 Days From Day 1 to End of Study (EOS) Visit (Month 42) in the OLE Treatment Period

    Baseline (Core) was defined as Baseline prior to double-blind treatment in the core studies (ZX008-1501/ZX008-1502, and ZX008-1504 Cohort 2). Participants in 1504- Cohort 1 and de novo participants (who entered 1503 without having been in any of the core studies) did not have a Baseline (Core), and were not included in the analysis of this outcome measure. The total number of convulsive seizures from Day 1 to EOS was divided by the total number of days from Day 1 to EOS with nonmissing diary data and the result was then multiplied by 28 to get a 28-day convulsive seizure frequency (CSF). The change from Baseline for any individual participant was calculated by subtracting the Baseline (Core) from the post-baseline value. Monthly (28 day) CSF was based on electronic diary data obtained for each participant.

    Time frame: From Day 1 to End of OLE Treatment Period (EOS Visit - up to Month 42), compared to Baseline (Core)

  2. Change From Baseline (Core) in Convulsive Seizure Frequency Per 28 Days From Month 2 to EOS (Month 42) in the OLE Treatment Period

    Baseline (Core) was defined as Baseline prior to double-blind treatment in the core studies. Participants in 1504-Cohort 1 and de novo participants did not have a Baseline (Core), and were not included in the analysis of this outcome measure. The total number of convulsive seizures from Month 2 to EOS was divided by the total number of days from Month 2 to EOS with nonmissing diary data and the result was then multiplied by 28 to get a 28-day CSF. The change from Baseline for any individual participant was calculated by subtracting the Baseline (Core) from the post-baseline value. Monthly (28 day) CSF was based on electronic diary data obtained for each participant.

    Time frame: From Month 2 to End of OLE Treatment Period (EOS Visit - up to Month 42), compared to Baseline (Core)

  3. Convulsive Seizure Frequency (CSF) Per 28 Days During the OLE Treatment Period (to Month 36)

    Monthly (28 day) CSF was based on electronic diary data obtained for each participant. The total number of convulsive seizures in the ith interval (CSF in OLE, where, i=1, 2, 3, … , 14 ) was divided by the total number of days in the ith interval with nonmissing diary data and the result was then multiplied by 28 to get a 28-day CSF of OLE.

    Time frame: At Month 1, Month 2, Month 3, Month 4-6, Month 7-9, Month 10-12, Month 13-15, Month 16-18, Month 19-21, Month 22-24, Month 25-27, Month 28-30, Month 31-33, and Month 34-36

  4. Convulsive Seizure Frequency (CSF) by Mean Daily Dose During the Overall OLE Treatment Period

    Convulsive seizure frequency over time, reported as per 28 days was analyzed by the actual dose administered. Participants were grouped into low (0.2 to \<0.4 mg/kg), medium (0.4 to \<0.6 mg/kg), and high dose (\>0.6 mg/kg) groups depending on their mean daily doses of ZX008 during the OLE Treatment period. For each participant, the seizure frequency per 28 days was calculated as the number of seizures recorded during the period, divided by the number of days in the period and multiplied by 28. The convulsive seizure frequency was calculated from all available data collected.

    Time frame: From Day 1 to End of OLE Treatment Period - End of Study (EOS) Visit (Month 42)

  5. Percentage of Participants With Changes in Antiepileptic Drug (AED) Medications During First 6 Months of OLE Treatment Period

    Participants in the study were required to be on stable background therapy for the first 6 months of treatment, after which background AEDs could be reduced or withdrawn so long as one background AED remained. The percentage of participants who had changes in dose or type of concomitant AED medications during the first, second, third, fourth, fifth, and sixth months were analyzed and reported.

    Time frame: At Month 1, 2, 3, 4 , 5, and 6 of OLE Treatment Period

07

Results

Posted Sep 25, 2023

Participant flow

The study started to enroll participants in Jun 2016 and concluded in Jan 2023. Participants who completed 14 weeks treatment in any of the core studies ZX008-1501/ZX008-1502 (NCT02682927), or ZX008-1504 (NCT02926898) Cohort 2, or completed ZX008-1504 Cohort 1 study, and de novo participants were eligible to participate in this study.

Enrollment
Participant flow — Enrollment
MilestoneNot TreatedAny ZX008 Open Label Dose
Started1374
Completed0374
Not completed10
Withdrew: Other10
Treatment
Participant flow — Treatment
MilestoneNot TreatedAny ZX008 Open Label Dose
Started0374
Completed049
Not completed0325
Withdrew: Adverse event011
Withdrew: Death03
Withdrew: Family decision01
Withdrew: Ip approved and subject moved to commercial drug01
Withdrew: Lack of efficacy048
Withdrew: Non-compliance with e-diary01
Withdrew: Physician decision02
Withdrew: Subject has transitioned to study 1900 ole study0225
Withdrew: Subject needed to take prohibited medication01
Withdrew: Subject transferred to direct access programme01
Withdrew: Switching to commercially available drug011
Withdrew: Transitioned to commercial supply of medication01
Withdrew: Withdrawal by caregiver01
Withdrew: Withdrawal by sponsor due to lack of compliance01
Withdrew: Withdrawal by subject016
Withdrew: Reason unknown01

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Open-label Extension (OLE) Treatment Period

Treatment-emergent adverse events (TEAE) were defined as any AEs that based on start date information occurs after the first intake of study treatment.

Time frame:
From Day 1 to End of OLE Treatment Period - End of Study (EOS) Visit (Month 42)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Open-label Extension (OLE) Treatment Period
percentage of participantsAny ZX008 Open Label Dose
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Open-label Extension (OLE) Treatment Period98.1
PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the OLE Treatment Period

A TEAE was defined as any AE that based on start date information occurs after the first intake of study treatment. Percentage of participants with TEAEs leading to withdrawal from IMP during OLE Treatment Period were reported.

Time frame:
From Day 1 to End of OLE Treatment Period - EOS Visit (Month 42)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the OLE Treatment Period
percentage of participantsAny ZX008 Open Label Dose
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the OLE Treatment Period3.5
PrimaryPercentage of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the OLE Treatment Period

Serious Adverse event (SAE) was defined as any untoward medical occurrence that at any dose: • results in death, • is life-threatening threatening, • results in initial inpatient hospitalization or prolongation of hospitalization, •results in persistent or significant disability or incapacity, • results in a congenital anomaly/birth defect, • results in any medically significant event that did not meet any of the other 5 SAE criteria, but which was judged by a physician to potentially jeopardize the participant or require medical or surgical intervention to prevent one of the above outcomes listed as an SAE criterion.

Time frame:
From Day 1 to End of OLE Treatment Period - EOS Visit (Month 42)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the OLE Treatment Period
percentage of participantsAny ZX008 Open Label Dose
Percentage of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the OLE Treatment Period26.5
SecondaryChange From Baseline (Core) in Convulsive Seizure Frequency Per 28 Days From Day 1 to End of Study (EOS) Visit (Month 42) in the OLE Treatment Period

Baseline (Core) was defined as Baseline prior to double-blind treatment in the core studies (ZX008-1501/ZX008-1502, and ZX008-1504 Cohort 2). Participants in 1504- Cohort 1 and de novo participants (who entered 1503 without having been in any of the core studies) did not have a Baseline (Core), and were not included in the analysis of this outcome measure. The total number of convulsive seizures from Day 1 to EOS was divided by the total number of days from Day 1 to EOS with nonmissing diary data and the result was then multiplied by 28 to get a 28-day convulsive seizure frequency (CSF). The change from Baseline for any individual participant was calculated by subtracting the Baseline (Core) from the post-baseline value. Monthly (28 day) CSF was based on electronic diary data obtained for each participant.

Time frame:
From Day 1 to End of OLE Treatment Period (EOS Visit - up to Month 42), compared to Baseline (Core)
Reported as:
Median · seizure frequency per 28 days
Change From Baseline (Core) in Convulsive Seizure Frequency Per 28 Days From Day 1 to End of Study (EOS) Visit (Month 42) in the OLE Treatment Period
seizure frequency per 28 daysAny ZX008 Open Label Dose
Change From Baseline (Core) in Convulsive Seizure Frequency Per 28 Days From Day 1 to End of Study (EOS) Visit (Month 42) in the OLE Treatment Period-6.67 (-1757.8 to 751.3)
SecondaryChange From Baseline (Core) in Convulsive Seizure Frequency Per 28 Days From Month 2 to EOS (Month 42) in the OLE Treatment Period

Baseline (Core) was defined as Baseline prior to double-blind treatment in the core studies. Participants in 1504-Cohort 1 and de novo participants did not have a Baseline (Core), and were not included in the analysis of this outcome measure. The total number of convulsive seizures from Month 2 to EOS was divided by the total number of days from Month 2 to EOS with nonmissing diary data and the result was then multiplied by 28 to get a 28-day CSF. The change from Baseline for any individual participant was calculated by subtracting the Baseline (Core) from the post-baseline value. Monthly (28 day) CSF was based on electronic diary data obtained for each participant.

Time frame:
From Month 2 to End of OLE Treatment Period (EOS Visit - up to Month 42), compared to Baseline (Core)
Reported as:
Median · seizure frequency per 28 days
Change From Baseline (Core) in Convulsive Seizure Frequency Per 28 Days From Month 2 to EOS (Month 42) in the OLE Treatment Period
seizure frequency per 28 daysAny ZX008 Open Label Dose
Change From Baseline (Core) in Convulsive Seizure Frequency Per 28 Days From Month 2 to EOS (Month 42) in the OLE Treatment Period-7.04 (-1986.9 to 816.4)
SecondaryConvulsive Seizure Frequency (CSF) Per 28 Days During the OLE Treatment Period (to Month 36)

Monthly (28 day) CSF was based on electronic diary data obtained for each participant. The total number of convulsive seizures in the ith interval (CSF in OLE, where, i=1, 2, 3, … , 14 ) was divided by the total number of days in the ith interval with nonmissing diary data and the result was then multiplied by 28 to get a 28-day CSF of OLE.

Time frame:
At Month 1, Month 2, Month 3, Month 4-6, Month 7-9, Month 10-12, Month 13-15, Month 16-18, Month 19-21, Month 22-24, Month 25-27, Month 28-30, Month 31-33, and Month 34-36
Reported as:
Median · seizure frequency per 28 days
Convulsive Seizure Frequency (CSF) Per 28 Days During the OLE Treatment Period (to Month 36)
seizure frequency per 28 daysAny ZX008 Open Label Dose
Month 16.53 (0.0 to 4876.9)
Month 24.67 (0.0 to 3392.7)
Month 34.67 (0.0 to 2593.7)
Month 4-64.36 (0.0 to 1725.5)
Month 7-93.82 (0.0 to 310.8)
Month 10-124.04 (0.0 to 362.4)
Month 13-153.11 (0.0 to 215.0)
Month 16-183.42 (0.0 to 243.3)
Month 19-213.42 (0.0 to 372.4)
Month 22-242.80 (0.0 to 489.5)
Month 25-272.80 (0.0 to 747.3)
Month 28-302.80 (0.0 to 242.5)
Month 31-333.21 (0.0 to 224.0)
Month 34-362.74 (0.0 to 56.0)
SecondaryConvulsive Seizure Frequency (CSF) by Mean Daily Dose During the Overall OLE Treatment Period

Convulsive seizure frequency over time, reported as per 28 days was analyzed by the actual dose administered. Participants were grouped into low (0.2 to \<0.4 mg/kg), medium (0.4 to \<0.6 mg/kg), and high dose (\>0.6 mg/kg) groups depending on their mean daily doses of ZX008 during the OLE Treatment period. For each participant, the seizure frequency per 28 days was calculated as the number of seizures recorded during the period, divided by the number of days in the period and multiplied by 28. The convulsive seizure frequency was calculated from all available data collected.

Time frame:
From Day 1 to End of OLE Treatment Period - End of Study (EOS) Visit (Month 42)
Reported as:
Median · seizure frequency per 28 days
Convulsive Seizure Frequency (CSF) by Mean Daily Dose During the Overall OLE Treatment Period
seizure frequency per 28 daysAny ZX008 Open Label Dose
ZX008 Low Dose (0 - <0.4 mg/kg/day)3.94 (0.0 to 2215.3)
ZX008 Medium Dose (0.4 - <0.6 mg/kg/day)4.80 (0.0 to 113.6)
ZX008 High Dose (>=0.6 mg/kg/day)6.00 (0.1 to 942.8)
SecondaryPercentage of Participants With Changes in Antiepileptic Drug (AED) Medications During First 6 Months of OLE Treatment Period

Participants in the study were required to be on stable background therapy for the first 6 months of treatment, after which background AEDs could be reduced or withdrawn so long as one background AED remained. The percentage of participants who had changes in dose or type of concomitant AED medications during the first, second, third, fourth, fifth, and sixth months were analyzed and reported.

Time frame:
At Month 1, 2, 3, 4 , 5, and 6 of OLE Treatment Period
Reported as:
Number · percentage of participants
Percentage of Participants With Changes in Antiepileptic Drug (AED) Medications During First 6 Months of OLE Treatment Period
percentage of participantsAny ZX008 Open Label Dose
OLE Month 15.2
OLE Month 27.1
OLE Month 37.4
OLE Month 48.3
OLE Month 56.8
OLE Month 69.6

Adverse events

Collected over From Day 1 up to 42 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Any ZX008 Open Label Dose3/374 (0.8%)99/374 (26.5%)342/374 (91.4%)
Most frequent serious events
Showing 10 of 92
Most frequent serious events
EventAny ZX008 Open Label Dose
SeizureNervous system disorders21/374
Status epilepticusNervous system disorders15/374
PneumoniaInfections and infestations12/374
InfluenzaInfections and infestations7/374
Seizure clusterNervous system disorders6/374
Viral infectionInfections and infestations5/374
Change in seizure presentationNervous system disorders5/374
Sudden unexplained death in epilepsyGeneral disorders3/374
GastroenteritisInfections and infestations3/374
Lower respiratory tract infectionInfections and infestations3/374
Most frequent other events
Showing 10 of 27
Most frequent other events
EventAny ZX008 Open Label Dose
PyrexiaGeneral disorders112/374
NasopharyngitisInfections and infestations104/374
Decreased appetiteMetabolism and nutrition disorders100/374
Blood glucose decreasedInvestigations88/374
DiarrhoeaGastrointestinal disorders73/374
Echocardiogram abnormalInvestigations67/374
Upper respiratory tract infectionInfections and infestations65/374
SeizureNervous system disorders46/374
InfluenzaInfections and infestations45/374
VomitingGastrointestinal disorders39/374

Baseline characteristics

Baseline characteristics refers to the Safety (SAF) population which included all enrolled participants who received at least one dose of ZX008 during the open label extension (OLE). As pre-specified in the SAP, participant Demographics and Baseline Characteristics were summarized for the safety population.

Age, Continuous
Age, Continuous(years)Any ZX008 Open Label Dose
Mean10.3 ± 6.12
Age, Customized
Age, Customized(Participants)Any ZX008 Open Label Dose
<6 years92
6-18 years250
>18 years32
Sex: Female, Male
Sex: Female, Male(Participants)Any ZX008 Open Label Dose
Female172
Male202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Any ZX008 Open Label Dose
White275
Black or African American5
Asian31
American Indian or Alaska Native2
Other17
Not Reported44
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Any ZX008 Open Label Dose
Hispanic or Latino44
Not Hispanic or Latino267
Not Reported55
Unknown8
08

Study locations

67 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Center for Neurosciences - Tucson
    Tucson, Arizona 85718, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • Rady Children's Hospital San Diego
    San Diego, California 92123, United States
  • University of California San Francisco
    San Francisco, California 94158, United States
  • The Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • NW FL Clinical Research Group, LLC
    Gulf Breeze, Florida 32561, United States
  • Miami Children's Hospital Brain Institute
    Miami, Florida 33155, United States
  • Neurology and Epilepsy Research Center
    Orlando, Florida 32819, United States
  • Clinical Integrative Research Center of Atlanta, Panda Neurology
    Atlanta, Georgia 30328, United States
  • Ann and Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Children's Hospital Of Michigan
    Detroit, Michigan 48201, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Minnesota Epilepsy Group, P.A.
    Saint Paul, Minnesota 55102, United States
  • Institute of Neurology and Neurosurgery at St. Barnabus
    Livingston, New Jersey 07039, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44103, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Le Bonheur Children's Hospital
    Memphis, Tennessee 38103, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76104, United States
  • University of Utah
    Salt Lake City, Utah 84113, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • MultiCare Institute for Research & Innovation
    Tacoma, Washington 98405, United States
  • Melbourne Brain Centre Austin Hospital
    Heidelberg, Australia
  • Children's Health Queensland Hospital and Health Service at Lady Cilento Children's Hospital
    South Brisbane, Australia
  • The Children's Hospital Westmead Dept. of Neurology and Neurosurgery
    Westmead, Australia
  • Universitair Ziekenhuis Antwerpen
    Edegem, Belgium
  • Centre Hospitalier Universitaire Sainte-Justine
    Montreal, Canada
  • British Columbia Children's Hospital
    Vancouver, Canada
  • Danish National Epilepsy Centre
    Dianalund, Denmark
  • CHU Amiens-Picardie Service De Neurologie Pediatrique
    Amiens, France
  • CHU De Bordeaux Service De Pédiatrie Médicale
    Bordeaux, France
  • CHRU Lille Antenne Pédiatrique Du CIC - Hôpital Jeanne De Flandre
    Lille, France
  • HOPITAL DEL LA TIMONE - HOPITAL HENRI GASTAUT Hôpital De La Timone Neurologie Pédiatrique Pneumologie Pédiatrique Et Médecine Infantile
    Marseille, France
  • Hôpital Robert Debré Pôle: Pédiatrie Médicale Service: Neurologie Et Maladies Métaboliques
    Paris, France
  • Hôpital Universitaire Necker-Enfants Malades Service de neurologie pédiatrique Centre de référence épilepsies rares (CReER)
    Paris, France
  • DRK Kliniken Berlin - Westend Epilepsiezentrum / Neuropaediatrie
    Berlin, Germany
  • Krankenhaus Mara Epilepsie-Zentrum Bethel
    Bielefeld, Germany
  • Universitaetsklinikum Freiburg Zentrum fuer Kinder- und Jugendmedizin
    Freiburg im Breisgau, Germany
  • Universitaetsklinikum Jena Klinik fuer Kinder- und Jugendmedizin Neuropaediatrie
    Jena, Germany
  • Universitaetsklinikum Schleswig-Holstein Campus Kiel Klinik fuer Neuropaediatrie
    Kiel, Germany
  • Kleinwachau Saechsisches Epilepsiezentrum Radeberg gemeinnuetzige GmbH
    Radeberg, Germany
  • Universitaetsklinik fuer Kinder- und Jugendmedizin Abteilung III
    Tübingen, Germany
  • Schoen Klinik Vogtareuth Neuropaediatrie und Neurologische Rehabilitation, Epilepsiezentrum fuer Kinder und Jugendlische, Tagesklinik fuer Neuropaediatrie
    Vogtareuth, Germany
  • AOU Anna Meyer Clinica di Neurologia Pediatrica
    Florence, Italy
  • Istituto Pediatrico Giannina Gaslini Dipartimento di Neurologia
    Genova, Italy
  • A.O. Carlo Poma
    Mantua, Italy
  • Istituto Neurologica Carlo Besta
    Milan, Italy
  • Ospedale Fatebenefratelli e Oftalmico
    Milan, Italy
  • Policlinico A. Gemelli
    Roma, Italy
  • U.O. Neurologia Dipartimento di Neuroscienze Ospedale Pediatrico Bambino Gesù
    Roma, Italy
  • Ospedale Civile Maggiore di Borgo Trento - Ospedale della Donna e del Bambino
    Verona, Italy
  • Saitama Children's Medical Center
    Saitama, Japan
  • National Epilepsy Center Shizuoka Institute of Epilepsy and Neurological Disorders
    Shizuoka, Japan
  • Tokyo Women's Medical University Hospital
    Tokyo, Japan
  • Kempenhaeghe
    Heeze, Netherlands
  • Stichting Epilepsie Instellingen Nederland
    Zwolle, Netherlands
  • Hospital Sant Joan de Déu
    Barcelona, Spain
  • Hospital Ruber Internacional Primera Planta Servicio de Neurologia
    Madrid, Spain
  • Clinica Universitaria de Navarra Fase 4. Segunda planta, Consulta de Pediatria
    Pamplona, Spain
  • Birmingham Children Hospital NHS Foundation Trust
    Birmingham, United Kingdom
  • Institute of Neurosciences Queen Elizabeth University Hospital
    Glasgow, United Kingdom
  • Alder Hey Hospital
    Liverpool, United Kingdom
  • Great Ormond Street Hospital for Children NHS Foundation Trust
    London, United Kingdom
  • St. Thomas Hospital
    London, United Kingdom
  • Sheffield Children's Hospital
    Sheffield, United Kingdom
09

References and documents

Publications

  • Scheffer IE, Nabbout R, Lagae L, Devinsky O, Auvin S, Thiele EA, Wirrell EC, Polster T, Specchio N, Pringsheim M, Imai K, Lock MD, Langlois M, Roper RZ, Lothe A, Sullivan J. Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome. Epilepsia. 2025 Jun;66(6):1919-1932. doi: 10.1111/epi.18342. Epub 2025 Mar 12. PubMed 40072476 ↗
  • Cross JH, Galer BS, Gil-Nagel A, Devinsky O, Ceulemans B, Lagae L, Schoonjans AS, Donner E, Wirrell E, Kothare S, Agarwal A, Lock M, Gammaitoni AR. Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure. 2021 Dec;93:154-159. doi: 10.1016/j.seizure.2021.10.024. Epub 2021 Nov 2. PubMed 34768178 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Jan 2023, 79 months.

Results were first posted in Sep 2023, 7 months after primary completion.

Of 15 phase 3 interventional studies under Epilepsies, Myoclonic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 72. This study's 79 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2016
First posted
Jul 6, 2016
StartActual
Jun 8, 2016
Primary completionActual
Jan 27, 2023
CompletionActual
Jan 27, 2023
Results first posted
Sep 25, 2023
Last update
Jul 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02823145
Responsible party
Sponsor
First posted
Jul 6, 2016
Start date
Jun 8, 2016
Primary completion
Jan 27, 2023
Completion
Jan 27, 2023
Results posted
Sep 25, 2023
Last update
Jul 14, 2025

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenfluramine

Start the discussion